Setting priorities for development of emerging interventions against childhood diarrhoea

Citation for published version:
Bhutta, ZA, Zipursky, A, Wazny, K, Levine, MM, Black, RE, Bassani, DG, Shantosham, M, Freedman, SB, Grange, A, Kosek, M, Keenan, W, Petri, W, Campbell, H & Rudan, I 2013, 'Setting priorities for development of emerging interventions against childhood diarrhoea' Journal of Global Health, vol 3, no. 1, pp. 10302. DOI: 10.7189/jogh.03.010302

Digital Object Identifier (DOI):
10.7189/jogh.03.010302

Link:
Link to publication record in Edinburgh Research Explorer

Document Version:
Publisher's PDF, also known as Version of record

Published In:
Journal of Global Health

Publisher Rights Statement:
Available under Open Access

General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.
Diarrhoeal diseases are still among the leading causes of childhood mortality in the world, contributing to more than 800,000 deaths in children younger than 5 years of age in 2010 [1,2]. It is widely acknowledged that a major portion of those deaths can be prevented if universal coverage of known effective interventions could be achieved [3,4]. However, recent evaluations have shown that the uptake of those interventions is rather disappointing, with only a minority of all children with life-threatening episodes of diarrhoea in low- and middle-income countries having access to trained health care providers and receiving appropriate treatment [5–7]. Thus, novel diarrhoea control strategies that balance investments in scaling up of existing interventions and the development of novel approaches, technologies and ideas are needed.

The importance of childhood diarrhoea as a global public health problem is in stark contrast to the size of the research community focused on the issue and the amount of funding committed to studying the disease [8]. However, there have been several efforts in recent years that aimed to assess feasibility and potential effectiveness of 10 emerging health interventions against childhood diarrhoea. Twelve international experts were invited to take part in a CHNRI priority setting process. This group used 12 different criteria relevant to successful development and implementation of the emerging interventions, nine of which were retained in the final analysis. They showed most collective optimism towards developing household or community-level water treatment, followed by sustainable, affordable latrine options; those two emerging interventions were followed by antibiotics for Cryptosporidium diarrhoea, and oral or transcutaneous enteric vaccine development.
EMERGING INTERVENTIONS AGAINST
CHILDHOOD DIARRHOEA

The 10 emerging interventions were chosen for evaluation from the results of a previous CHNRI exercise [12] and further consultation with a paediatric gastroenterologist (Table 1). The previous exercise [12] brought together 10 teams, corresponding to research avenues in childhood diarrhoea. Each team separately generated and ranked their set of research questions. While one team focused specifically on emerging interventions, many teams generated research priorities related to emerging interventions and thus, we considered novel interventions proposed by all teams for inclusion in this exercise. We aimed to be open–minded and inclusive in the selection of these interventions, appreciating that some of them may still need considerable work before being ready for implementation.

EXPERT OPINION EXERCISE

The CHNRI methodology for priority setting in investments in health research and technologies was proposed as a systematic tool that can be used to develop research policy and/or prioritize investments in health research [13–14]. The CHNRI method consists of the following steps: (i) investors and policy–makers define the context of the problem and identify the criteria for priority–setting; (ii) technical experts generate research priorities and score them against the pre–defined criteria; and, (iii) other stakeholders decide on the weight of the criteria, intended to reflect a wider societal system of values. The method has been described elsewhere, and many examples of implementation have been published [15–18].

A group of 12 leading international experts were invited to participate in the expert opinion exercise. The group was instructed to use a downstream (ie, broad, long–term) approach and focus solely on emerging interventions. During October 2012 the group ranked 10 emerging interventions according to a number of criteria used to identify priorities for research support in the area of childhood diarrhoea. A

The second level of priority was assigned to probiotics and prebiotics; combination vaccine for *Cryptosporidium*, *Shigella* and enterotoxigenic *Escherichia coli* (ETEC); and to the use of anti–emetics in case management. The lowest level of enthusiasm was expressed towards the treatment or prevention (vaccines) of environmental enteropathy, CFTR inhibitors, and the inhibitors of intestinal epithelial secretion in the treatment of diarrhoea. The exercise suggested that there are relatively few novel or feasible interventions in the course of development to address the high residual disease burden of diarrhoea in children.

**Table 1.** The consolidated list of 10 emerging interventions against childhood diarrhoea

| 1. Probiotics and prebiotics |
| 2. Anti–emetics |
| 3. Treatment or prevention (vaccines) of environmental enteropathy |
| 4. Sustainable, affordable latrine options |
| 5. Household– or community–level water treatment |
| 6. CFTR inhibitors |
| 7. Inhibitors of intestinal epithelial function in the treatment of diarrhoea |
| 8. Antibiotic therapy of *Cryptosporidium* diarrhoea |
| 9. Oral or transcutaneous vaccine development |
| 10. Combination vaccine for *Cryptosporidium*, *Shigella*, and enterotoxigenic *Escherichia coli* (ETEC) |

CFTR = cystic fibrosis transmembrane conductance regulator
modified version of CHNRI’s conceptual framework (Table 2) was used and included 12 criteria for prioritization of emerging interventions: 1) answerability (in an ethical way); 2) low development cost; 3) low product cost; 4) low implementation cost; 5) predicted efficacy; 6) likelihood of deliverability; 7) likelihood of affordability; 8) likelihood of sustainability; 9) maximum potential impact on mortality burden reduction; 10) likelihood of acceptability to health workers; 11) likelihood of acceptability to end users; 12) predicted impact on equity [19].

All experts invited to participate in the exercise received a brief (1 page) background document containing information on each of the 10 emerging interventions. This document also explained why each of the 12 criteria was chosen and how to apply them to each emerging intervention. The experts were free to challenge all information provided to them in a background document and to share further personal knowledge or opinion with the group. The experts were invited by e-mail to score, independently of each other, all emerging interventions according to the 12 agreed CHNRI criteria.

The scoring of the emerging interventions was conducted using a points system that assigned a value of 1 to positive answers (yes) and 0 to negative answers (no). When an expert assigned the answer “undecided” to a given criteria, the value of 0.5 points was used. Conversely, when the expert declared to be insufficiently informed on a given issue to answer the question, the input was deemed missing and not scored (or penalized). Each research question/theme received a score for all 12 criteria from each expert and the final score was calculated as the average of the ratios of the sum of all points given over the maximum possible number of points (excluding missing inputs). Such final score ranged from 0 to 100% and represents a direct measure of ‘collective optimism’ for a given emerging intervention.

In the initial exercise, we included different components of the cost (development cost, product cost, implementation cost and affordability), but those 4 criteria are in fact a single criterion (cost). We therefore decided to exclude 3 criteria to ensure the remaining criteria were relatively independent of one another (similar to principal component analysis). If all 4 were kept in the exercise, this would give

Table 2. Specific questions used to assess whether the proposed research themes (eg, emerging interventions) satisfy the 12 priority-setting criteria

| 1. Answerability in an ethical way (“1” for Yes; “0” for No; “0.5” for Undecided) |
| --- |
| • Do we have a sufficient research and development capacity to make the intervention available on the market by 2025? |
| • Do we have a sufficient level of funding support to make the intervention available on the market by 2025? |
| • Would you say that it is likely that the remaining technical hurdles can be overcome to make the intervention available on the market by 2025? |

| 2. Low development cost (“1” for Yes; “0” for No; “0.5” for Undecided) |
| --- |
| • How much will it cost to get from the current stage of development to commercial availability of each emerging intervention below? |
| a. <US$ 1 billion |
| b. <US$ 500 million |
| c. <US$ 100 million |

| 3. Low product cost (“1” for Yes; “0” for No; “0.5” for Undecided) |
| --- |
| • Is it likely to be a low-cost intervention (ie, <US$ 3.50 per unit)? |

| 4. Low implementation cost (“1” for Yes; “0” for No; “0.5” for Undecided) |
| --- |
| • Can we use the existing delivery mechanisms without major modifications (eg, training, infrastructure)? |

| 5. Affordability (“1” for Yes; “0” for No; “0.5” for Undecided) |
| --- |
| • Is achievement of a near-universal coverage likely to be affordable to most developing countries? |

| 6. Predicted efficacy (0–100%) |
| --- |
| • Please assess the likelihood (0–100%) that adequately powered randomized controlled trials of the interventions conducted in developing countries would consistently show statistically significant reduction in cause-specific mortality from childhood diarrhoea. |

| 7. Likely maximum potential impact on mortality burden |
| --- |
| • Please predict the proportion of deaths in children under 5 years of age due to diarrhoea that could be averted if the complete coverage with the emerging interventions listed below could be achieved? |

| 8–9. Deliverability and Sustainability (“1” for Yes; “0” for No; “0.5” for Undecided) |
| --- |
| • Taking into account (i) the infrastructure and resources required to deliver emerging interventions listed below (eg, human resources, health facilities, communication and transport infrastructure); (ii) the resources likely to be available to implement the emerging interventions at the time of introduction; (iii) overall capacity of the governments (eg, adequacy of government regulation, monitoring and enforcement; governmental intersectoral coordination), and (iv) internal and external partnership required for delivery of interventions (eg, partnership with civil society and external donor agencies), would you say that the emerging interventions would be: |
| a. Deliverable at the time of introduction? |
| b. Sustainable for at least 10 years after the time of introduction? |

| 10–12. Acceptability to health workers; Acceptability to end-users; and Impact on equity (“1” for Yes; “0” for No; “0.5” for Undecided) |
| --- |
| • Taking into account the overall context, intervention complexity, health workers’ behaviour and the end-user population at the time of introduction: |
| a. Would health workers be likely to comply with implementation guidelines? |
| b. Would end-users be likely to fully accept the intervention? |
| c. Would you say that the proposed intervention has the overall potential to improve equity after 10 years following the introduction? |
kept out of the final score calculation. After the exclusion, mean scores given to each criterion by the experts was calculated. The overall research priority score (RPS) was calculated as a mean of the 9 intermediate criteria scores. The scores given to all 10 emerging interventions are presented in Table 3.

**MAIN FINDINGS**

As shown in Table 3, the panel declared most of their collective optimism towards developing household- or community-level water treatment, followed by sustainable, affordable latrine options. The key strengths of those interventions were high likelihood of efficacy, acceptability both among health workers and end-users, and positive impact on equity in the population. Those two interventions were followed by antibiotic therapy for *Cryptosporidium* diarrhoea, and oral or transcutaneous enteric vaccine development. These two emerging interventions had similar scores as the two top-ranked, but their impact on equity in the population was deemed less certain.

The second priority level was assigned to probiotics and prebiotics; combination vaccine for *Cryptosporidium*, *Shigella*, and enterotoxigenic *Escherichia coli* (ETEC); and the use of anti-emetics in diarrhoea case management. The key weaknesses of the combination vaccine were uncertain answerability and high predicted cost of development, while the key uncertainty over the use of probiotics and anti-emetics is related to very low optimism towards their potential for the reduction of the overall burden of diarrhoea.

The lowest level of optimism was expressed towards the treatment or prevention of environmental enteropathy, cystic

---

Table 3. The results of the CHNRI exercise: 10 emerging interventions with 9 intermediate scores and an overall research priority score (RPS)

| Rank | Emerging intervention | Answerability development cost | Low development cost | Likelihood of efficacy | Max burden reduction potential | Deliverable Sustainable | Acceptable to health workers | Acceptable to end users | Impact on equity | Research investment priority score |
|------|-----------------------|--------------------------------|----------------------|-----------------------|-------------------------------|-------------------------|-----------------------------|--------------------------|----------------|----------------------------------|
| 1    | Household- or community-level water treatment | 78 | 47 | 100 | 44 | 68 | 77 | 95 | 86 | 100 | 77.3 |
| 2    | Sustainable, affordable latrine options | 64 | 60 | 95 | 45 | 41 | 86 | 91 | 95 | 91 | 74.4 |
| 3    | Antibiotic therapy of *Cryptosporidium* diarrhoea | 72 | 49 | 82 | 23 | 64 | 77 | 86 | 91 | 70 | 68.2 |
| 4    | Oral or transcutaneous vaccine development | 44 | 36 | 77 | 39 | 64 | 64 | 100 | 95 | 82 | 66.9 |
| 5    | Probiotics and prebiotics | 74 | 54 | 60 | 10 | 59 | 86 | 77 | 86 | 64 | 63.5 |
| 6    | *Cryptosporidium*, *Shigella*, and enterotoxigenic *Escherichia coli* (ETEC) | 42 | 29 | 82 | 33 | 55 | 68 | 100 | 86 | 73 | 63.1 |
| 7    | Anti-emetics | 65 | 50 | 59 | 7 | 64 | 67 | 91 | 95 | 43 | 60.4 |
| 8    | Treatment or prevention (vaccines) of environmental enteropathy | 29 | 53 | 41 | 39 | 45 | 41 | 80 | 60 | 60 | 49.9 |
| 9    | CFTR inhibitors | 35 | 42 | 55 | 9 | 15 | 30 | 61 | 61 | 28 | 37.4 |
| 10   | Inhibitors of intestinal epithelial function in the treatment of diarrhoea | 38 | 36 | 45 | 21 | 36 | 36 | 44 | 56 | 39 | 39.1 |

CFTR – cystic fibrosis transmembrane conductance regulator
Acknowledgements: None.

Funding: Bill and Melinda Gates Foundation.

Ethical approval: Not required.

Authorship declaration: ZB, AZ and KW prepared background reading material and moderated different stages of the expert meeting. IR and HC designed a modified CHNRI process for setting research priorities in emerging health technologies. MML, REB, DB, MS, SF, AG, MK, WK, ZB, HC, IR and WP provided the ideas on emerging interventions and scored the emerging interventions. IR and ZB drafted the paper with other various authors’ contribution in revision. All authors provided important intellectual input at different stages of the work.

Competing interests: All authors have completed the Unified Competing Interest form at www.icmje.org/coi披露.pdf (available on request from the corresponding author) and declare support from Bill and Melinda Gates Foundation for the submitted work. The authors declare no financial relationships with any organizations that might have an interest in the submitted work.

REFERENCES

1. Black RE, Cousens S, Johnson HL, Lawn JE, Rudan I, Bassani DG, et al. Global, regional, and national causes of child mortality in 2008: a systematic analysis. Lancet. 2010;375:1969-87. Medline:20466419 doi:10.1016/S0140-6736(10)60549-1

2. Walker CL, Rudan I, Liu L, Nair H, Theodoratou E, Bhutta ZA, et al. Global burden of childhood pneumonia and diarrhoea. Lancet. 2013;381:1405-16. Medline:23582727 doi:10.1016/S0140-6736(13)60222-6

3. Bhutta ZA, Das JK, Walker N, Rizvi A, Campbell H, Rudan I, et al; Lancet Diarrhoea and Pneumonia Interventions Study Group. Interventions to address deaths from childhood pneumonia and diarrhoea equitably: what works and at what cost? Lancet. 2013;381:1417-29. Medline:23582723 doi:10.1016/S0140-6736(13)60648-0

4. Chopra M, Mason E, Borrazzo J, Campbell H, Rudan I, Liu L, et al. Ending of preventable deaths from pneumonia and diarrhoea: an achievable goal. Lancet. 2013;381:1499-506. Medline:23582721 doi:10.1016/S0140-6736(13)60319-0

5. Wilson SE, Morris SS, Gilbert SS, Mosites E, Hackleman R, Weum KLM, et al. Scaling up access to Oral Rehydration Solution for diarrhea: Learning from historical experience in low- and high-performing countries. J Glob Health. 2013;3:010404. doi:10.7189/jogh.03.010404

6. Horwood C, Vermaak K, Rollins N, Haskins L, Nkosi F, Qazi S. An evaluation of the quality of IMCI assessments among IMCI trained health workers in South Africa. PLoS ONE. 2009;4:e5937. Medline:19507747 doi:10.3329/jhpn.v27i3.3374

7. Gill CJ, Young M, Schroder K, Carvajal-Velez L, McNabb M, Aboubaker S, et al. Bottlenecks, barriers, and solutions: results from multicountry consultations focused on reduction of childhood pneumonia and diarrhoea deaths. Lancet. 2013;381:1487-98. Medline:23582720 doi:10.1016/S0140-6736(13)60314-1

8. Rudan I, El Arifeen S, Black RE, Campbell H. Childhood pneumonia and diarrhoea: setting our priorities right. Lancet Infect Dis. 2007;7:56-61. Medline:17182344 doi:10.1016/S1473-3099(06)70687-9

9. Kosek M, Lanata CF, Black RE, Walker DG, Snyder JD, Salam MA, et al. Directing diarrhoeal disease research towards disease-burden reduction. J Health Popul Nutr. 2009;27:319-31. Medline:19577747 doi:10.3329/jhpn.v27i3.3374

10. Fontaine O, Kosek M, Bhatnagar S, Boschi-Pinto C, Chan KY, Guggan G, et al. Setting research priorities to reduce global mortality from childhood diarrhoea by 2015. PLoS Med. 2009;6:e41. Medline:19278292 doi:10.1371/journal.pmed.1000041

CONCLUSION

In contrast to very large significance that childhood diarrhoea still has as a public health problem in low and middle income countries, this exercise suggested that relatively few novel interventions can be considered feasible at this point. The experts were most optimistic about the potential for Water and Sanitation Hygiene (WASH) interventions to be efficacious and reduce inequities. Although there are high development costs associated with most of the emerging interventions, investments in this sector will help reduce inequities and reduce the burden of childhood diarrhoea. In synergy with powerful interventions that are currently available, diarrhoeal mortality could be significantly reduced in the next 15 years.
Correspondence to:
Professor Igor Rudan
Centre for Population Health Sciences
The University of Edinburgh Medical School
Teviot Place
Edinburgh EH8 9AG
Scotland, UK
igor.rudan@ed.ac.uk

References

11 Zipursky A, Wazny K, Black RE, Keenan W, Duggan C, Olness K, et al. Global action plan for childhood diarrhoea: developing research priorities. J Glob Health. 2013;3:010406. doi:10.7189/jogh.03.010406

12 Wazny K, Zipursky A, Black RE, Curtis V, Duggan C, Guerrant R, et al. Setting research priorities to reduce mortality and morbidity of childhood diarrhoeal disease in the next 15 years. PLoS Med. 2013;10:e1001446. Medline:23690756 doi:10.1371/journal.pmed.1001446

13 Rudan I, Chopra M, Kapiriri L, Gibson J, Lansang MA, Carneiro I, et al. Setting priorities in global child health research investments: Universal challenges and conceptual framework. Croat Med J. 2008;49:307-17. Medline:18581609 doi:10.3325/cmj.2008.3.307

14 Rudan I, Gibson JL, Ameratunga S, El Arifeen S, Bhutta ZA, Black M, et al. Setting Priorities in Global Child Health Research Investments: Guidelines for implementation of the CHNRI Method. Croat Med J. 2008;49:720-33. Medline:19090596 doi:10.3325/cmj.2008.49.720

15 Rudan I, El Arifeen S, Bhutta ZA, Black RE, Brooks A, Chan KY, et al. Setting research priorities to reduce global mortality from childhood pneumonia by 2015. PLoS Med. 2011;8:e1001099. Medline:21980266 doi:10.1371/journal.pmed.1001099

16 Tomlinson M, Swartz L, Officer A, Chan KY, Rudan I, Saxena S. Research priorities for health of people with disabilities: an expert opinion exercise. Lancet. 2009;374:1857-62. Medline:19944866 doi:10.1016/S0140-6736(09)61910-3

17 Lawn JE, Bahl R, Bergstrom S, Bhutta ZA, Darmstadt GL, Ellis M, et al. Setting research priorities to reduce almost one million deaths from birth asphyxia by 2015. PLoS Med. 2011;8:e1000389. Medline:21305038 doi:10.1371/journal.pmed.1000389

18 George A, Young M, Bang A, Chan KY, Rudan I, Victora CG, et al. GAPPS expert group on community based strategies and constraints. Setting implementation research priorities to reduce preterm births and stillbirths at the community level. PLoS Med. 2011;8:e1000380. Medline:21245907 doi:10.1371/journal.pmed.1000380

19 Rudan I, Theodoratou E, Zgaga L, Nair H, Chan KY, Tomlinson M, et al. Setting priorities for development of emerging interventions against childhood pneumonia, meningitis and influenza. J Glob Health. 2012;2:010304. Medline:23198129 doi:10.7189/jogh.01.010304

Correspondence to:
Professor Igor Rudan
Centre for Population Health Sciences
The University of Edinburgh Medical School
Teviot Place
Edinburgh EH8 9AG
Scotland, UK
igor.rudan@ed.ac.uk